Tags

Type your tag names separated by a space and hit enter

The immunogenicity of intradermal influenza vaccination in COPD patients.
Vaccine. 2010 May 28; 28(24):4045-51.V

Abstract

We evaluated the immunogenicity of a reduced-dose intradermal trivalent, inactivated, split-virion seasonal influenza vaccine compared to that of a conventional intramuscular vaccination in chronic obstructive pulmonary disease (COPD) patients. One hundred and fifty-six COPD patients randomly received either 0.2 ml (6 microg hemagglutinin (HA) per strain) split into two-site intradermal (ID) injections or a single 0.5 ml (15 microg HA per strain) intramuscular (IM) injection. Geometric mean titers, seroconversion factors, seroconversion rates and seroprotection rates at 4 weeks post-vaccination in the ID group were less than those in the IM group. Only the seroconversion factor to influenza B in the ID group was statistically less than in the IM group (18.8 in the ID group, n=81 versus 37.3 in the IM group, n=75, p=0.045). Nevertheless, each strain of the ID vaccination met all the Committee for Proprietary Medicinal Products (CPMP) criteria. Seroprotection rates were above 60% throughout the year in influenza A (H3N2), for at least 6 months in influenza A (H1N1) and at least 4 weeks in influenza B in both ID and IM groups. The reduced-dose intradermal vaccination may be considered for use in COPD patients in a vaccine shortage situation.

Links

Publisher Full Text
Aggregator Full Text

Authors+Show Affiliations

Chuaychoo B
Division of Respiratory Disease and Tuberculosis, Department of Medicine, Siriraj Hospital, Mahidol University, 2 Pranok Road, BangkokNoi, Bangkok 10700, Thailand. bchuaychoo@gmail.com
Wongsurakiat P
No affiliation info available
Nana A
No affiliation info available
Kositanont U
No affiliation info available
Maranetra KN
No affiliation info available

MeSH

AdultAgedAged, 80 and overAntibodies, ViralAntibody FormationFemaleHemagglutination Inhibition TestsHemagglutinin Glycoproteins, Influenza VirusHumansInfluenza A Virus, H1N1 SubtypeInfluenza A Virus, H3N2 SubtypeInfluenza VaccinesInfluenza, HumanInjections, IntradermalInjections, IntramuscularMaleMiddle AgedPulmonary Disease, Chronic Obstructive

Pub Type(s)

Comparative Study
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

20412877

Citation

Chuaychoo, Benjamas, et al. "The Immunogenicity of Intradermal Influenza Vaccination in COPD Patients." Vaccine, vol. 28, no. 24, 2010, pp. 4045-51.
Chuaychoo B, Wongsurakiat P, Nana A, et al. The immunogenicity of intradermal influenza vaccination in COPD patients. Vaccine. 2010;28(24):4045-51.
Chuaychoo, B., Wongsurakiat, P., Nana, A., Kositanont, U., & Maranetra, K. N. (2010). The immunogenicity of intradermal influenza vaccination in COPD patients. Vaccine, 28(24), 4045-51. https://doi.org/10.1016/j.vaccine.2010.04.006
Chuaychoo B, et al. The Immunogenicity of Intradermal Influenza Vaccination in COPD Patients. Vaccine. 2010 May 28;28(24):4045-51. PubMed PMID: 20412877.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The immunogenicity of intradermal influenza vaccination in COPD patients. AU - Chuaychoo,Benjamas, AU - Wongsurakiat,Phunsup, AU - Nana,Arth, AU - Kositanont,Uraiwan, AU - Maranetra,Khun Nanta, Y1 - 2010/04/20/ PY - 2009/08/25/received PY - 2010/04/01/revised PY - 2010/04/07/accepted PY - 2010/4/24/entrez PY - 2010/4/24/pubmed PY - 2010/8/28/medline SP - 4045 EP - 51 JF - Vaccine JO - Vaccine VL - 28 IS - 24 N2 - We evaluated the immunogenicity of a reduced-dose intradermal trivalent, inactivated, split-virion seasonal influenza vaccine compared to that of a conventional intramuscular vaccination in chronic obstructive pulmonary disease (COPD) patients. One hundred and fifty-six COPD patients randomly received either 0.2 ml (6 microg hemagglutinin (HA) per strain) split into two-site intradermal (ID) injections or a single 0.5 ml (15 microg HA per strain) intramuscular (IM) injection. Geometric mean titers, seroconversion factors, seroconversion rates and seroprotection rates at 4 weeks post-vaccination in the ID group were less than those in the IM group. Only the seroconversion factor to influenza B in the ID group was statistically less than in the IM group (18.8 in the ID group, n=81 versus 37.3 in the IM group, n=75, p=0.045). Nevertheless, each strain of the ID vaccination met all the Committee for Proprietary Medicinal Products (CPMP) criteria. Seroprotection rates were above 60% throughout the year in influenza A (H3N2), for at least 6 months in influenza A (H1N1) and at least 4 weeks in influenza B in both ID and IM groups. The reduced-dose intradermal vaccination may be considered for use in COPD patients in a vaccine shortage situation. SN - 1873-2518 UR - https://www.unboundmedicine.com/medline/citation/20412877/The_immunogenicity_of_intradermal_influenza_vaccination_in_COPD_patients_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0264-410X(10)00499-8 DB - PRIME DP - Unbound Medicine ER -